Quantcast

Latest Melanoma Stories

2014-10-22 08:27:12

NEW YORK, Oct. 22, 2014 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors reducing the potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical...

2014-10-21 08:35:00

NEW YORK, Oct. 21, 2014 /PRNewswire/ -- Macro Risk Advisors (MRA), a leading provider of global market risk analysis and execution services for institutional investors, today announced that it raised $401,000 in its third annual charitable trading day on October 14(th). All of the net commissions earned from option, stock and ETF trades, will be donated to four diverse organizations selected by MRA. The Cancer Research Institute and the Melanoma Research Fund at the Perlmutter Cancer...

2014-10-09 23:06:16

Provectus Biopharmaceuticals Collaborates with ERT’s COA Experts to Understand Patient Perspective during Melanoma Drug Development PHILADELPHIA, PA (PRWEB) October 09, 2014 ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced that Provectus Biopharmaceuticals (NYSE MKT: PVCT) is collaborating with ERT’s Clinical Outcome Assessment (COA) consultants on their Phase III trial of agent PV-10 for intralesional (IL)...

2014-10-09 08:24:34

NEW YORK, Oct. 9, 2014 /PRNewswire/ -- A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for...

2014-10-03 23:05:44

Dr. William Groff discusses the importance of sun protection from a young age following report that sunscreen use among youth has dropped. San Diego, CA (PRWEB) October 03, 2014 An August 21, 2014 report from CBS News tells of a study which found that even as melanoma rates are rising, sunscreen use among teenagers has declined. Melanoma is a particularly deadly form of skin cancer, which can occur with too much sun or UV ray exposure. Skin cancer is easily preventable with proper sun...

2014-10-02 12:28:31

LONDON, Oct. 2, 2014 /PRNewswire/ -- This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies covers three principle therapies that have been in the...

2014-09-29 23:03:24

In May, the website for mesothelioma patients and their families reported on the first mesothelioma patient accepted into a U.K. clinical trial of the drug, which was recently approved by the FDA for use in treating advanced melanoma patients. New York, NY (PRWEB) September 29, 2014 MesotheliomaHelp.org is calling attention today to the U.S. Food and Drug Administration’s accelerated approval of Keytruda (pembrolizumab; MK-3475) for the treatment of patients with advanced or surgically...

2014-09-29 08:30:43

- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept. 29, 2014 /PRNewswire/ -- Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented today at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. Invented by Array BioPharma Inc. (NASDAQ: ARRY) and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2....

2014-09-25 23:03:26

The North American Dermatology treatment devices market report defines and segments the concerned market in North America, with analysis and forecast of revenue. http://www.micromarketmonitor.com/market/north-america-dermatology-treatment-devices-4338799582.html (PRWEB) September 25, 2014 The North American Dermatology treatment devices market report defines and segments the concerned market in North America, with analysis and forecast of revenue. The Dermatology treatment devices...

2014-09-18 12:29:43

The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that at one year post-launch in the United States, 54 percent of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or metastatic melanoma, compared with 49...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.